Carl Sandler Net Worth

The estimated Net Worth of Carl Forest Sandler is at least $2.41 Million dollars as of 22 March 2022. Mr. Sandler owns over 1,927 units of Enochian Biosciences Inc stock worth over $2,231,241 and over the last 5 years he sold ENOB stock worth over $78,845. In addition, he makes $97,136 as Independent Director at Enochian Biosciences Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Sandler ENOB stock SEC Form 4 insiders trading

Carl has made over 2 trades of the Enochian Biosciences Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 1,927 units of ENOB stock worth $17,459 on 22 March 2022.

The largest trade he's ever made was selling 6,798 units of Enochian Biosciences Inc stock on 18 February 2022 worth over $61,386. On average, Carl trades about 1,454 units every 5 days since 2019. As of 22 March 2022 he still owns at least 3,187,487 units of Enochian Biosciences Inc stock.

You can see the complete history of Mr. Sandler stock trades at the bottom of the page.

Carl Sandler biography

Carl Sandler serves as Independent Director of the Company. Mr. Sandler has built numerous consumer-facing technology and healthcare brands. He was the CEO of Enochian BioPharma, Inc. prior to its acquisition by the Registrant and has been the Manager of Weird Science, LLC since March of 2017. Mr. Sandler is a widely respected thought leader, journalist and speaker on issues related to public health, HIV/AIDS, sex and sexuality. He has spoken extensively at HIV/AIDS conferences worldwide about innovative uses of technology in public health. In addition to his journalism and speaking engagements, and prior to his position with Weird Science, Mr. Sandler was the Manager of DH Services, LLC, an application developer, and the CEO of True Sons Grooming, a subscription service.

What is the salary of Carl Sandler?

As the Independent Director of Enochian Biosciences Inc, the total compensation of Carl Sandler at Enochian Biosciences Inc is $97,136. There are 6 executives at Enochian Biosciences Inc getting paid more, with Mark Dybul having the highest compensation of $1,964,450.

How old is Carl Sandler?

Carl Sandler is 48, he's been the Independent Director of Enochian Biosciences Inc since 2018. There are 9 older and no younger executives at Enochian Biosciences Inc. The oldest executive at Enochian Biosciences Inc is Carol Brosgart, 69, who is the Independent Director.

What's Carl Sandler's mailing address?

Carl's mailing address filed with the SEC is 330 EAST 33RD STREET, APARTMENT 3A, NEW YORK, NY, 10016.

Insiders trading at Enochian Biosciences Inc

Over the last 7 years, insiders at Enochian Biosciences Inc have traded over $2,106,789 worth of Enochian Biosciences Inc stock and bought 552,919 units worth $3,888,612 . The most active insiders traders include Gregg H Alton, Rene Sindlev, and Serhat Gumrukcu. On average, Enochian Biosciences Inc executives and independent directors trade stock every 91 days with the average trade being worth of $35,881. The most recent stock trade was executed by Serhat Gumrukcu on 18 May 2022, trading 253,493 units of ENOB stock currently worth $2,027,944.

What does Enochian Biosciences Inc do?

enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and cancer. the company’s lead candidate eno-1001 (pre-ind) is a potentially sterilizing cure for hiv/aids. eno-2001 is an hiv vaccine in preclinical stage, and its additional compounds eno-4001 (phase three asset), eno-4002, eno-5001, and eno-3001 are in discovery stages for prevention relapse in colon cancer patients. enochian biosciences is headquartered in los angeles, california.

Complete history of Mr. Sandler stock trades at Enochian Biosciences Inc

Enochian Biosciences Inc executives and stock owners

Enochian Biosciences Inc executives and other stock owners filed with the SEC include:

• Mark Dybul,
  Executive Vice Chairman of the Board, Principal Executive Officer
• Luisa Puche,
  Chief Financial Officer
• Dr. Mark R. Dybul M.D.,
  Chief Exec. Officer & Director
• Luisa Puche,
  Chief Financial Officer
• Evelyn D'An,
  Independent Director
• James Sapirstein,
  Independent Director
• Carl Sandler,
  Independent Director
• Henrik Gronfeldt-Sorensen,
  Director
• Rene Sindlev,
  Independent Chairman of the Board
• Gregg Alton,
  Independent Director
• Carol Brosgart,
  Independent Director
• Dr. François Binette M.Sc., Ph.D.,
  Exec. VP for R&D
• Greg Duczynski Ph.D.,
  Sr. VP for Clinical Operations
• Dr. Serhat Gümrükcü,
  Co-Founder & Inventor
• Tung Nguyen,
  Head of Molecular Biology
• Dr. Wenshi Wang,
  Sr. VP of Operations
• Dr. Serhat Gümrükcü,
  Co-Founder & Inventor
• Francois Binette,
  Executive VP for R&D
• Jayne Mc Nicol,
  Director
• Eric Jean Marie Leire,,
  
• Carl Forest Sandler,
  
• Serhat Gumrukcu,
  10% owner
• Anderson Wittekind William,
  
• Science Llc Weird,